Literature DB >> 8589612

Prognostic significance of p53 over-expression in thin melanomas.

L E Sparrow1, D R English, P J Heenan, H J Dawkins, J Taran.   

Abstract

Metastasis by thin melanomas is uncommon and unpredictable. In order to assess the prognostic value of p53 expression, p53 immunohistochemical staining was evaluated in 20 thin melanomas with documented metastasis and in 20 control tumours which failed to metastasize. Tumours selected were less than 1 mm thick and were individually matched for tumour thickness, date of excision and patient age and sex. The relative risk of metastasis given p53 overexpression was 1.5 (95% confidence interval 0.4-5.3; p = 0.53). Further quantitative analysis for p53 between the two groups did not demonstrate a significant difference (p = 0.08). These results are consistent with there being no association between p53 overexpression in thin melanomas and risk of metastasis, however, the sample size was small, and the existence of such an association cannot be ruled out with confidence. For the 20 thin melanomas which metastasized, there was no association between the proportion of cells positive for p53 and length of the relapse-free period (correlation coefficient = 0.02, p = 0.94).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589612     DOI: 10.1097/00008390-199512000-00001

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  2 in total

1.  p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Authors:  Tamara Terzian; Enrique C Torchia; Daisy Dai; Steven E Robinson; Kazutoshi Murao; Regan A Stiegmann; Victoria Gonzalez; Glen M Boyle; Marianne B Powell; Pamela M Pollock; Guillermina Lozano; William A Robinson; Dennis R Roop; Neil F Box
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

2.  p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.

Authors:  J M Karjalainen; M J Eskelinen; J K Kellokoski; M Reinikainen; E M Alhava; V M Kosma
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.